CDH1 and lung cancer: In addition, the core fucosylated E-cadherin can be used as a prognostic indicator for lung cancer patients 44, and an AlphaLISA analysis method for quantifying serum core-fucosylated E-cadherin as a biomarker of metastatic lung adenocarcinoma has been developed 45.